1. Articles in category: Information

    1-24 of 279 1 2 3 4 ... 10 11 12 »
    1. Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

      Int J Radiat Oncol Biol Phys. 2018 Jan 09;:

      Authors: Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL

      Read Full Article
    2. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    3. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2304-2319

      Authors: Arnhold V, Schmelz K, Proba J, Winkler A, Wünschel J, Toedling J, Deubzer HE, Künkele A, Eggert A, Schulte JH, Hundsdoerfer P

      Read Full Article
      Mentions: MYCN
    4. MELK is a novel therapeutic target in high-risk neuroblastoma.

      MELK is a novel therapeutic target in high-risk neuroblastoma.

      Oncotarget. 2018 Jan 05;9(2):2591-2602

      Authors: Guan S, Lu J, Zhao Y, Yu Y, Li H, Chen Z, Shi Z, Liang H, Wang M, Guo K, Chen X, Sun W, Bieerkehazhi S, Xu X, Sun S, Agarwal S, Yang J

      Abstract Maternal embryonic leucine zipper kinase (MELK) is known to modulate intracellular signaling and control cellular processes. However, the role of MELK in oncogenesis is not well defined.

      Read Full Article
      Mentions: MYCN
    5. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.

      Biochim Biophys Acta. 2018 Feb 02;:

      Authors: Ferrucci F, Ciaccio R, Monticelli S, Pigini P, di Giacomo S, Purgato S, Erriquez D, Bernardoni R, Norris M, Haber M, Milazzo G, Perini G

      Read Full Article
      Mentions: MYCN
    6. SPECT/CT Mibg Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      SPECT/CT MIBG Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma.

      Clin Nucl Med. 2018 Feb 03;:

      Authors: Liu B, Servaes S, Zhuang H

      Abstract BACKGROUND: Planar whole-body imaging with I-radiolabeled metaiodobenzylguanidine (I-MIBG) is routinely used in the follow-up evaluation of neuroblastoma. In recent years, SPECT with integrated low-dose CT (SPECT/CT) has become more accessible.

      Read Full Article
      Mentions: Imaging MIBG
    7. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

      Lancet Child Adolesc Health. 2018 Jan;2(1):25-34

      Authors: de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL

      Read Full Article
      Mentions: COG Chemotherapy
    8. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.

      PLoS Med. 2018 Jan;15(1):e1002497

      Authors: Srinivasan P, Wu X, Basu M, Rossi C, Sandler AD

      Read Full Article
      Mentions: PD-1
    9. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    10. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

      Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

      Cancer Gene Ther. 2016 Nov;23(11):371-372

      Authors: Mohammadi M, Goodarzi M, Jaafari MR, Mirzaei HR, Mirzaei H

      Abstract Neuroblastoma (NB) is known as a pediatric neoplasm that is associated with variable histopathological features. The use of biomarkers contributes to the monitoring and treatment of various malignancies such as NB.

      Read Full Article
    11. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      Invest New Drugs. 2016 Dec;34(6):685-692

      Authors: Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

      Abstract Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.

      Read Full Article
      Mentions: Treatment Relapse
    12. FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      Oncotarget. 2017 Dec 15;8(66):109985-109999

      Authors: Lange I, Espinoza-Fuenzalida I, Ali MW, Serrano LE, Koomoa DT

      Abstract Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression.

      Read Full Article
    13. c-MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification.

      c-MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification.

      Cancer Discov. 2017 Dec 28;:

      Authors: Zimmerman MW, Liu Y, He S, Durbin AD, Abraham BJ, Easton J, Shao Y, Xu B, Zhu S, Zhang X, Li Z, Weichert-Leahey N, Young RA, Zhang J, Look AT

      Read Full Article
      Mentions: MYCN
    14. Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.

      Coexpression network analysis identifies transcriptional modules associated with genomic alterations in neuroblastoma.

      Biochim Biophys Acta. 2017 Dec 13;:

      Authors: Yang L, Li Y, Wei Z, Chang X

      Abstract Neuroblastoma is a highly complex and heterogeneous cancer in children. Acquired genomic alterations including MYCN amplification, 1p deletion and 11q deletion are important risk factors and biomarkers in neuroblastoma.

      Read Full Article
      Mentions: MYCN Biomarkers
    15. Apeiron Announces Publication of Clinical Data with Anti-GD2 Antibody Demonstrating Efficacy in ...

      VIENNA, Austria, Dec. 18, 2017 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced the publication of a successful clinical study in high-risk neuroblastoma patients in the December issue of mAbs, a prominent journal in the monoclonal ...

      Read Full Article
    16. Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Drugs Today (Barc). 2017 Sep;53(9):469-476

      Authors: Greenwood K, Foster JH

      Abstract Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblastoma cells. The incorporation of dinutuximab into standard treatment regimens for patients with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy.

      Read Full Article
      Mentions: Antibody Treatment
    17. MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

      MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

      Oncotarget. 2017 Nov 10;8(56):95293-95302

      Authors: Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV

      Read Full Article
      Mentions: Immunotherapy MYCN
    18. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

      Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.

      Pediatr Hematol Oncol. 2017 Dec 04;:1-12

      Authors: Whittle SB, Williamson KC, Russell HV

      Abstract High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk.

      Read Full Article
    19. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

      CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.

      J Clin Invest. 2017 Dec 04;:

      Authors: Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K

      Read Full Article
      Mentions: MYCN
    20. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      J Pediatr Surg. 2017 Nov 09;:

      Authors: Amano H, Uchida H, Tanaka Y, Tainaka T, Mori M, Oguma E, Kishimoto H, Kawashima H, Arakawa Y, Hanada R, Koh K

      Read Full Article
    21. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

      Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy.

      Biol Blood Marrow Transplant. 2017 Nov 27;:

      Authors: Nassin ML, Nicolaou E, Gurbuxani S, Cohn SL, Cunningham JM, LaBelle JL

      Read Full Article
      Mentions: Immunotherapy
    22. Surgical Treatment of Neuroblastoma.

      Surgical Treatment of Neuroblastoma.

      Isr Med Assoc J. 2017 Nov;19(11):691-695

      Authors: Ben Barak A, Golan H, Waldman D, Arkovitz MS

      Abstract BACKGROUND: Neuroblastoma is the most common non-central nervous system (CNS) solid malignant tumor in children. The surgical treatment of high-risk neuroblastoma presents a challenge, and the benefits of aggressive surgical resection have been called into question. OBJECTIVES: To examine our experience with surgical resection of neuroblastoma.

      Read Full Article
      Mentions: Treatment
    1-24 of 279 1 2 3 4 ... 10 11 12 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) COG
  4. Researches in the News

    1. (4 articles) MYCN
    2. (1 articles) PD-1
    3. (1 articles) Imaging
  5. General Informations in the News

    1. (1 articles) Treatment
  6. Treatments in the News

    1. (1 articles) MIBG
    2. (1 articles) Relapse
    3. (1 articles) Refractory
    4. (1 articles) Chemotherapy